Review of clinical studies and recommendation for a therapeutic flow chart for diabetic macular edema.

Angiogenesis Inhibitors / therapeutic use Diabetes Mellitus Diabetic Retinopathy / complications Humans Intravitreal Injections Laser Coagulation Macular Edema / diagnosis Vascular Endothelial Growth Factor A
Clinical evidence Diabetic macular edema Review Therapeutic flow chart

Journal

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
ISSN: 1435-702X
Titre abrégé: Graefes Arch Clin Exp Ophthalmol
Pays: Germany
ID NLM: 8205248

Informations de publication

Date de publication:
Apr 2021
Historique:
received: 25 05 2020
accepted: 10 09 2020
revised: 03 09 2020
pubmed: 1 10 2020
medline: 19 8 2021
entrez: 30 9 2020
Statut: ppublish

Résumé

Diabetic macular edema (DME), characterized by exudative fluid accumulation in the macula, is the most common form of sight-threatening retinopathy in patients with diabetes. The management of DME has changed considerably in recent years, especially following the development of intravitreal anti-vascular endothelial growth factor therapy which has emerged as a first-line therapy for center-involved DME. Laser treatment, intravitreal steroid therapy, and vitrectomy are also important treatment options for DME. We believe that it is important to choose the most appropriate treatment option for DME based on the clinical evidences, in addition to the careful consideration of individual patients' general or ocular condition, DME characteristics, patients' motivation, and compliance to the treatment in real-world clinical practice. In this review, we have summarized important clinical evidences for the main treatments for DME, presented an expert review for these evidences, and proposed a recommended therapeutic flow chart for DME. We hope that our review of the clinical evidences and the recommended therapeutic flow chart for DME will contribute to better treatment outcome for DME.

Identifiants

DOI: 10.1007/s00417-020-04936-w PMID: 32997288
pubmed: 32997288
doi: 10.1007/s00417-020-04936-w
pii: 10.1007/s00417-020-04936-w
doi:

Substances chimiques

Angiogenesis Inhibitors 0
Vascular Endothelial Growth Factor A 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

815-836

Références

Tan GS, Cheung N, Simó R, Cheung GC, Wong TY (2017) Diabetic macular oedema. Lancet Diabetes Endocrinol 5:143–155
pubmed: 27496796 doi: 10.1016/S2213-8587(16)30052-3
Miller K, Fortun JA (2018) Diabetic macular edema: current understanding, pharmacologic treatment options, and developing therapies. Asia Pac J Ophthalmol (Phila) 7:28–35
Kodjikian L, Bellocq D, Bandello F, Loewenstein A, Chakravarthy U, Koh A, Augustin A, de Smet MD, Chhablani J, Tufail A, García-Layana A, Sudhalkar A, Mathis T (2019) First-line treatment algorithm and guidelines in center-involving diabetic macular edema. Eur J Ophthalmol 29:573–584
pubmed: 31238719 doi: 10.1177/1120672119857511
Bandello F, Cunha-Vaz J, Chong NV, Lang GE, Massin P, Mitchell P, Porta M, Prünte C, Schlingemann R, Schmidt-Erfurth U (2012) New approaches for the treatment of diabetic macular oedema: recommendations by an expert panel. Eye (Lond) 26:485–493
doi: 10.1038/eye.2011.337
Kim EJ, Lin WV, Rodriguez SM, Chen A, Loya A, Weng CY (2019) Treatment of diabetic macular edema. Curr Diab Rep 19:68
pubmed: 31359157 doi: 10.1007/s11892-019-1188-4
Crosson JN, Mason L, Mason JO (2017) The role of focal laser in the anti-vascular endothelial growth factor era. Ophthalmol Eye Dis 21:1179172117738240
Blindbaek SL, Peto T, Grauslund J (2019) How do we evaluate the role of focal/grid photocoagulation in the treatment of diabetic macular edema? Acta Ophthalmol 97:339–346
pubmed: 30575304 doi: 10.1111/aos.13997
Li J, Paulus YM (2018) Advances in retinal laser therapy. Int J Ophthalmic Res 4:259–264
pubmed: 31681861 pmcid: 6824197 doi: 10.17554/j.issn.2409-5680.2018.04.70
Haritoglou C, Maier M, Neubauer AS, Augustin AJ (2020) Current concepts of pharmacotherapy of diabetic macular edema. Expert Opin Pharmacother 21:467–475
pubmed: 31957495 doi: 10.1080/14656566.2020.1713093
Berrocal MH, Acaba LA, Chenworth ML (2019) Surgical innovations in the treatment of diabetic macular edema and diabetic retinopathy. Curr Diab Rep 19:106
pubmed: 31529405 doi: 10.1007/s11892-019-1210-x
Early Treatment Diabetic Retinopathy Study research group (1985) Photocoagulation for diabetic macular edema. Early treatment diabetic retinopathy study report number 1. Arch Ophthalmol 103:1796–1806
doi: 10.1001/archopht.1985.01050120030015
Dugel PU, Layton A, Varma RB (2016) Diabetic macular edema diagnosis and treatment in the real world: an analysis of Medicare claims data (2008 to 2010). Ophthalmic Surg Lasers Imaging Retina 47:258–267
pubmed: 26985800 doi: 10.3928/23258160-20160229-09
Jiang S, Barner JC, Park C, Ling YL (2015) Treatment patterns of anti-vascular endothelial growth factor and laser therapy among patients with diabetic macular edema. J Manag Care Spec Pharm 21:735–741
pubmed: 26308221
Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, Ferris FL 3rd, Friedman SM, Glassman AR, Miller KM, Scott IU, Stockdale CR, Sun JK (2010) Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 117:1064–1077
doi: 10.1016/j.ophtha.2010.02.031
Elman MJ, Ayala A, Bressler NM, Browning D, Flaxel CJ, Glassman AR, Jampol LM, Stone TW, Diabetic Retinopathy Clinical Research Network (2015) Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. Ophthalmology 122:375–381
pubmed: 25439614 doi: 10.1016/j.ophtha.2014.08.047
Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, Sutter F, Simader C, Burian G, Gerstner O, Weichselberger A, RESTORE study group (2011) The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 118:615–625
doi: 10.1016/j.ophtha.2011.01.031 pubmed: 21459215
Schmidt-Erfurth U, Lang GE, Holz FG, Schlingemann RO, Lanzetta P, Massin P, Gerstner O, Bouazza AS, Shen H, Osborne A, Mitchell P, RESTORE Extension Study Group (2014) Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study. Ophthalmology 121:1045–1053
pubmed: 24491642 doi: 10.1016/j.ophtha.2013.11.041
Ishibashi T, Li X, Koh A, Lai TY, Lee FL, Lee WK, Ma Z, Ohji M, Tan N, Cha SB, Shamsazar J, Yau CL, REVEAL Study Group (2015) The REVEAL study: ranibizumab monotherapy or combined with laser versus laser monotherapy in Asian patients with diabetic macular edema. Ophthalmology 122:1402–1415
pubmed: 25983216 doi: 10.1016/j.ophtha.2015.02.006
Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, Gibson A, Sy J, Rundle AC, Hopkins JJ, Rubio RG, Ehrlich JS, RISE and RIDE Research Group (2012) Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 119:789–801
doi: 10.1016/j.ophtha.2011.12.039 pubmed: 22330964
Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L, Schlottmann PG, Rundle AC, Zhang J, Rubio RG, Adamis AP, Ehrlich JS, Hopkins JJ, RIDE and RISE Research Group (2013) Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 120:2013–2022
pubmed: 23706949 doi: 10.1016/j.ophtha.2013.02.034
Prünte C, Fajnkuchen F, Mahmood S, Ricci F, Hatz K, Studnička J, Bezlyak V, Parikh S, Stubbings WJ, Wenzel A, Figueira J, RETAIN Study Group (2016) Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study. Br J Ophthalmol 100:787–795
pubmed: 26453639 doi: 10.1136/bjophthalmol-2015-307249
Korobelnik JF, Do DV, Schmidt-Erfurth U, Boyer DS, Holz FG, Heier JS, Midena E, Kaiser PK, Terasaki H, Marcus DM, Nguyen QD, Jaffe GJ, Slakter JS, Simader C, Soo Y, Schmelter T, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Zeitz O, Metzig C, Brown DM (2014) Intravitreal aflibercept for diabetic macular edema. Ophthalmology 121:2247–2254
pubmed: 25012934 doi: 10.1016/j.ophtha.2014.05.006
Brown DM, Schmidt-Erfurth U, Do DV, Holz FG, Boyer DS, Midena E, Heier JS, Terasaki H, Kaiser PK, Marcus DM, Nguyen QD, Jaffe GJ, Slakter JS, Simader C, Soo Y, Schmelter T, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Zeitz O, Metzig C, Korobelnik JF (2015) Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID Studies. Ophthalmology 122:2044–2052
pubmed: 26198808 doi: 10.1016/j.ophtha.2015.06.017
Heier JS, Korobelnik JF, Brown DM, Schmidt-Erfurth U, Do DV, Midena E, Boyer DS, Terasaki H, Kaiser PK, Marcus DM, Nguyen QD, Jaffe GJ, Slakter JS, Simader C, Soo Y, Schmelter T, Vitti R, Berliner AJ, Zeitz O, Metzig C, Holz FG (2016) Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies. Ophthalmology 123:2376–2385
Baker CW, Glassman AR, Beaulieu WT, Antoszyk AN, Browning DJ, Chalam KV, Grover S, Jampol LM, Jhaveri CD, Melia M, Stockdale CR, Martin DF, Sun JK, Retina Network DRCR (2019) Effect of initial management with aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity: a randomized clinical trial. JAMA 321:1880–1894
pubmed: 31037289 pmcid: 6537845 doi: 10.1001/jama.2019.5790
Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Diabetic Retinopathy Clinical Research Network et al (2015) Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 372:1193–1203
pubmed: 25692915 doi: 10.1056/NEJMoa1414264
Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, Brucker AJ, Ferris FL, Hampton GR, Jhaveri C, Melia M, Beck RW, Diabetic retinopathy Clinical Research Network (2016) Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology 123:1351–1359
pubmed: 26935357 doi: 10.1016/j.ophtha.2016.02.022
Rahimy E, Shahlaee A, Khan MA, Ying GS, Maguire JI, Ho AC, Regillo CD, Hsu J (2016) Conversion to aflibercept after prior anti-vegf therapy for persistent diabetic macular edema. Am J Ophthalmol 164:118–127.e2
pubmed: 26748058 doi: 10.1016/j.ajo.2015.12.030
Chen YY, Chang PY, Wang JK (2017) Intravitreal aflibercept for patients with diabetic macular edema refractory to bevacizumab or ranibizumab: analysis of response to aflibercept. Asia Pac J Ophthalmol (Phila) 6:250–255
Ibrahim WS, Eldaly ZH, Saleh MG, Rateb MF, Aldoghaimy AH (2019) Switching to aflibercept in diabetic macular edema after unsatisfactory response to other anti-vascular endothelial growth factor drugs. Korean J Ophthalmol 33:122–130
pubmed: 30977321 pmcid: 6462479 doi: 10.3341/kjo.2018.0037
Bressler SB, Qin H, Beck RW, Chalam KV, Kim JE, Melia M, Wells JA 3rd, Diabetic Retinopathy Clinical Research Network (2012) Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab. Arch Ophthalmol 130:1153–1161
pubmed: 22965591 pmcid: 3543147 doi: 10.1001/archophthalmol.2012.1107
Sophie R, Lu N, Campochiaro PA (2015) Predictors of functional and anatomic outcomes in patients with diabetic macular edema treated with ranibizumab. Ophthalmology 122:1395–1401
doi: 10.1016/j.ophtha.2015.02.036 pubmed: 25870079
Dhoot DS, Baker K, Saroj N, Vitti R, Berliner AJ, Metzig C, Thompson D, Singh RP (2018) Baseline factors affecting changes in diabetic retinopathy severity scale score after intravitreal aflibercept or laser for diabetic macular edema: post hoc analyses from VISTA and VIVID. Ophthalmology 125:51–56
pubmed: 28764888 doi: 10.1016/j.ophtha.2017.06.029
Murakami T, Suzuma K, Uji A, Yoshitake S, Dodo Y, Fujimoto M, Yoshitake T, Miwa Y, Yoshimura N (2018) Association between characteristics of foveal cystoid spaces and short-term responsiveness to ranibizumab for diabetic macular edema. Jpn J Ophthalmol 62:292–301
pubmed: 29460019 doi: 10.1007/s10384-018-0575-8
Chen YP, Wu AL, Chuang CC, Chen SN (2019) Factors influencing clinical outcomes in patients with diabetic macular edema treated with intravitreal ranibizumab: comparison between responder and non-responder cases. Sci Rep 9:10952
pubmed: 31358777 pmcid: 6662817 doi: 10.1038/s41598-019-47241-1
Avery RL, Gordon GM (2016) Systemic safety of prolonged monthly anti-vascular endothelial growth factor therapy for diabetic macular edema: a systematic review and meta-analysis. JAMA Ophthalmol 134:21–29
pubmed: 26513684 doi: 10.1001/jamaophthalmol.2015.4070
Virgili G, Parravano M, Evans JR, Gordon I, Lucenteforte E (2017) Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. Cochrane Database Syst Rev 22:CD007419
Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E, Pyles EA, Yancopoulos GD, Stahl N, Wiegand SJ (2012) Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 15:171–185
pubmed: 22302382 pmcid: 3338918 doi: 10.1007/s10456-011-9249-6
Moradi A, Sepah YJ, Sadiq MA, Nasir H, Kherani S, Sophie R, Do DV, Nguyen QD (2013) Vascular endothelial growth factor trap-eye (Aflibercept) for the management of diabetic macular edema. World J Diabetes 4:303–309
pubmed: 24379921 pmcid: 3874490 doi: 10.4239/wjd.v4.i6.303
Stewart MW, Rosenfeld PJ, Penha FM, Wang F, Yehoshua Z, Bueno-Lopez E, Lopez PF (2012) Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye). Retina 32:434–457
pubmed: 22374154
Bressler SB, Ayala AR, Bressler NM, Melia M, Qin H, Ferris FL 3rd, Flaxel CJ, Friedman SM, Glassman AR, Jampol LM, Rauser ME, Diabetic Retinopathy Clinical Research Network (2016) Persistent macular thickening after ranibizumab treatment for diabetic macular edema with vision impairment. JAMA Ophthalmol 134:278–285
pubmed: 26746868 pmcid: 4786449 doi: 10.1001/jamaophthalmol.2015.5346
Bressler NM, Beaulieu WT, Glassman AR, Blinder KJ, Bressler SB, Jampol LM, Melia M, Wells JA 3rd, Diabetic Retinopathy Clinical Research Network (2018) Persistent macular thickening following intravitreous aflibercept, bevacizumab, or ranibizumab for central-involved diabetic macular edema with vision impairment: a secondary analysis of a randomized clinical trial. JAMA Ophthalmol 136:257–269
pubmed: 29392288 pmcid: 5885906 doi: 10.1001/jamaophthalmol.2017.6565
Gonzalez VH, Campbell J, Holekamp NM, Kiss S, Loewenstein A, Augustin AJ, Ma J, Ho AC, Patel V, Whitcup SM, Dugel PU (2016) Early and long-term responses to anti-vascular endothelial growth factor therapy in diabetic macular edema: analysis of protocol I data. Am J Ophthalmol 172:72–79
pubmed: 27644589 doi: 10.1016/j.ajo.2016.09.012
Koyanagi Y, Yoshida S, Kobayashi Y, Kubo Y, Nakama T, Ishikawa K, Nakao S, Hisatomi T, Ikeda Y, Oshima Y, Ishibashi T, Sonoda KH (2018) Visual outcomes based on early response to anti-vascular endothelial growth factor treatment for diabetic macular edema. Ophthalmologica 239:94–102
pubmed: 29316563 doi: 10.1159/000481711
Mori K, Yoshida S, Kobayashi Y, Ishikawa K, Nakao S, Hisatomi T, Haruta M, Isihibashi T, Sonoda KH (2020) Decrease in the number of microaneurysms in diabetic macular edema after anti-vascular endothelial growth factor therapy: implications for indocyanine green angiography-guided detection of refractory microaneurysms. Graefes Arch Clin Exp Ophthalmol 258:735–741
pubmed: 31960130 doi: 10.1007/s00417-020-04608-9
Moisseiev E, Abbassi S, Thinda S, Yoon J, Yiu G, Morse LS (2018) Subthreshold micropulse laser reduces anti-VEGF injection burden in patients with diabetic macular edema. Eur J Ophthalmol 28:68–73
pubmed: 28731494 doi: 10.5301/ejo.5001000
Liegl R, Langer J, Seidensticker F, Reznicek L, Haritoglou C, Ulbig MW, Neubauer AS, Kampik A, Kernt M (2014) Comparative evaluation of combined navigated laser photocoagulation and intravitreal ranibizumab in the treatment of diabetic macular edema. PLoS One 9:e113981
pubmed: 25541960 pmcid: 4277267 doi: 10.1371/journal.pone.0113981
Herold TR, Langer J, Vounotrypidis E, Kernt M, Liegl R, Priglinger SG (2018) 3-year-data of combined navigated laser photocoagulation (Navilas) and intravitreal ranibizumab compared to ranibizumab monotherapy in DME patients. PLoS One 13:e0202483
pubmed: 30138384 pmcid: 6107183 doi: 10.1371/journal.pone.0202483
Payne JF, Wykoff CC, Clark WL, Bruce BB, Boyer DS, Brown DM, TREX-DME Study Group (2017) Randomized trial of treat and extend ranibizumab with and without navigated laser for diabetic macular edema: TREX-DME 1 year outcomes. Ophthalmology 124:74–81
pubmed: 27836430 doi: 10.1016/j.ophtha.2016.09.021
Payne JF, Wykoff CC, Clark WL, Bruce BB, Boyer DS, Brown DM, TREX-DME Study Group (2019) Randomized trial of treat and extend ranibizumab with and without navigated laser versus monthly dosing for diabetic macular edema: TREX-DME 2-year outcomes. Am J Ophthalmol 202:91–99
pubmed: 30771333 doi: 10.1016/j.ajo.2019.02.005
Inagaki K, Hamada M, Ohkoshi K (2019) Minimally invasive laser treatment combined with intravitreal injection of anti-vascular endothelial growth factor for diabetic macular oedema. Sci Rep 9:7585
pubmed: 31110222 pmcid: 6527558 doi: 10.1038/s41598-019-44130-5
Takamura Y, Tomomatsu T, Matsumura T, Arimura S, Gozawa M, Takihara Y, Inatani M (2014) The effect of photocoagulation in ischemic areas to prevent recurrence of diabetic macular edema after intravitreal bevacizumab injection. Invest Ophthalmol Vis Sci 55:4741–4746
pubmed: 25028357 doi: 10.1167/iovs.14-14682
Browrn DM, Ou WC, Wong TP, Kim RY, Croft DE, Wykoff CC, DAVE Study Group (2018) Targeted retinal photocoagulation for diabetic macular edema with peripheral retinal nonperfusion: three-year randomized DAVE trial. Ophthalmology 125:683–690
doi: 10.1016/j.ophtha.2017.11.026
Kozak I, Oster SF, Cortes MA, Dowell D, Hartmann K, Kim JS, Freeman WR (2011) Clinical evaluation and treatment accuracy in diabetic macular edema using navigated laser photocoagulator NAVILAS. Ophthalmology 118:1119–1124
pubmed: 21269701 doi: 10.1016/j.ophtha.2010.10.007
Kernt M, Cheuteu RE, Cserhati S, Seidensticker F, Liegl RG, Lang J, Haritoglou C, Kampik A, Ulbig MW, Neubauer AS (2012) Pain and accuracy of focal laser treatment for diabetic macular edema using a retinal navigated laser (Navilas). Clin Ophthalmol 6:289–296
pubmed: 22393280 pmcid: 3292412 doi: 10.2147/OPTH.S27859
Kernt M, Cheuteu R, Vounotrypidis E, Haritoglou C, Kampik A, Ulbig MW, Neubauer AS (2011) Focal and panretinal photocoagulation with a navigated laser (NAVILAS®). Acta Ophthalmol 89:e662–e664
pubmed: 20946326 doi: 10.1111/j.1755-3768.2010.02017.x
Neubauer AS, Langer J, Liegl R, Haritoglou C, Wolf A, Kozak I, Seidensticker F, Ulbig M, Freeman WR, Kampik A, Kernt M (2013) Navigated macular laser decreases retreatment rate for diabetic macular edema: a comparison with conventional macular laser. Clin Ophthalmol 7:121–128
pubmed: 23345966 pmcid: 3551463
Jung JJ, Gallego-Pinazol R, Lleó-Pérez A, Huz JI, Barbazetto IA (2013) NAVILAS laser system focal laser treatment for diabetic macular edema - one year results of a case series. Open Ophthalmol J 7:48–53
pubmed: 24082979 pmcid: 3785058 doi: 10.2174/1874364101307010048
Kato F, Nozaki M, Kato A, Hasegawa N, Morita H, Yoshida M, Ogura Y (2018) Evaluation of navigated laser photocoagulation (Navilas 577+) for the treatment of refractory diabetic macular edema. J Ophthalmol 2018:3978514
pubmed: 29854426 pmcid: 5954871 doi: 10.1155/2018/3978514
Nozaki M, Kato A, Yasukawa T, Suzuki K, Yoshida M, Ogura Y (2019) Indocyanine green angiography-guided focal navigated laser photocoagulation for diabetic macular edema. Jpn J Ophthalmol 63:243–254
pubmed: 30806869 doi: 10.1007/s10384-019-00662-x
Su D, Hubschman JP (2017) A review of subthreshold micropulse laser and recent advances in retinal laser technology. Ophthalmol Therapy 6:1–6
doi: 10.1007/s40123-017-0077-7
Gawęcki M (2019) Micropulse laser treatment of retinal diseases. J Clin Med 8:242
pmcid: 6406510 doi: 10.3390/jcm8020242
Moore SM, Chao DL (2018) Application of subthreshold laser therapy in retinal diseases: a review. Expert Rev Ophthalmol 13:311–320
pubmed: 31692951 pmcid: 6831099 doi: 10.1080/17469899.2018.1555035
Figueira J, Khan J, Nunes S, Sivaprasad S, Rosa A, de Abreu JF, Cunha-Vaz JG, Chong NV (2009) Prospective randomised controlled trial comparing sub-threshold micropulse diode laser photocoagulation and conventional green laser for clinically significant diabetic macular oedema. Br J Ophthalmol 93:1341–1344
pubmed: 19054831 doi: 10.1136/bjo.2008.146712
Lavinsky D, Cardillo JA, Melo LA Jr, Dare A, Farah ME, Belfort R Jr (2011) Randomized clinical trial evaluating mETDRS versus normal or high-density micropulse photocoagulation for diabetic macular edema. Invest Ophthalmol Vis Sci 52:4314–4323
pubmed: 21345996 doi: 10.1167/iovs.10-6828
Luttrull JK, Musch DC, Mainster MA (2005) Subthreshold diode micro-pulse photocoagulation for the treatment of clinically significant diabetic macular oedema. Br J Ophthalmol 89:74–80
pubmed: 15615751 pmcid: 1772486 doi: 10.1136/bjo.2004.051540
Luttrull JK, Spink CJ (2006) Serial optical coherence tomography of subthreshold diode laser micropulse photocoagulation for diabetic macular edema. Ophthalmic Surg Lasers Imaging 37:370–377
pubmed: 17017196 doi: 10.3928/15428877-20060901-03
Othman IS, Eissa SA, Kotb MS, Sadek SH (2014) Subthreshold diode-laser micropulse photocoagulation as a primary and secondary line of treatment in management of diabetic macular edema. Clin Ophthalmol 8:653–659
pubmed: 24729679 pmcid: 3976239
Vujosevic S, Gatti V, Muraca A, Brambilla M, Villani E, Nucci P, Rossetti L, De Cillaʼ S (2020) Optical coherence tomography angiography changes after subthreshold micropulse yellow laser in diabetic macular edema. Retina 40:312–320
pubmed: 31972802 doi: 10.1097/IAE.0000000000002383
Vujosevic S, Frizziero L, Martini F, Bini S, Convento E, Cavarzeran F, Midena E (2018) Single retinal layer changes after subthreshold micropulse yellow laser in diabetic macular edema. Ophthalmic Surg Lasers Imaging Retina 49:e218–e225
pubmed: 30457660 doi: 10.3928/23258160-20181101-22
The diabetic retinopathy study research group (1981) Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of diabetic retinopathy study (DRS) findings, DRS report number 8. Ophthalmology 88:583–600
doi: 10.1016/S0161-6420(81)34978-1
Japanese Society of Ophthalmic Diabetology, Subcommittee on the Study of Diabetic Retinopathy Treatment, Sato Y, Kojimahara N, Kitano S, Kato S, Ando N, Yamaguchi N, Hori S (2012) Multicenter randomized clinical trial of retinal photocoagulation for preproliferative diabetic retinopathy. Jpn J Ophthalmol 56:52–59
doi: 10.1007/s10384-011-0095-2
Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, Nguyen HV, Aiello LM, Ferrara N, King GL (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480–1487
pubmed: 7526212 doi: 10.1056/NEJM199412013312203
Writing Committee for the Diabetic Retinopathy Clinical Research Network, Gross JG, Glassman AR, Jampol LM, Inusah S, Aiello LP, Antoszyk AN, Baker CW, Berger BB, Bressler NM, Browning D, Elman MJ, Ferris FL 3rd, Friedman SM, Marcus DM, Melia M, Stockdale CR, Sun JK, Beck RW (2015) Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA 314:2137–2146
doi: 10.1001/jama.2015.15217
Gross JG, Glassman AR, Liu D, Sun JK, Antoszyk AN, Baker CW, Bressler NM, Elman MJ, Ferris FL 3rd, Gardner TW, Jampol LM, Martin DF, Melia M, Stockdale CR, Beck RW, Diabetic Retinopathy Clinical Research Network (2018) Five-year outcomes of panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA Ophthalmol 136:1138–1148
pubmed: 30043039 pmcid: 6233839 doi: 10.1001/jamaophthalmol.2018.3255
Sivaprasad S, Prevost AT, Vasconcelos JC, Riddell A, Murphy C, Kelly J, Bainbridge J, Tudor-Edwards R, Hopkins D, Hykin P, CLARITY Study Group (2017) Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial. Lancet 389:2193–2203
pubmed: 28494920 doi: 10.1016/S0140-6736(17)31193-5
EVICR.net Study Group (2018) Ranibizumab plus panretinal photocoagulation versus panretinal photocoagulation alone for high-risk proliferative diabetic retinopathy (PROTEUS Study). Ophthalmology 125:691–700
doi: 10.1016/j.ophtha.2017.12.008
Obeid A, Gao X, Ali FS, Talcott KE, Aderman CM, Hyman L, Ho AC, Hsu J (2018) Loss to follow-up in patients with proliferative diabetic retinopathy after panretinal photocoagulation or intravitreal anti-VEGF injections. Ophthalmology 125:1386–1392
pubmed: 29606377 doi: 10.1016/j.ophtha.2018.02.034
Obeid A, Su D, Patel SN, Uhr JH, Borkar D, Gao X, Fineman MS, Regillo CD, Maguire JI, Garg SJ, Hsu J (2019) Outcomes of eyes lost to follow-up with proliferative diabetic retinopathy that received panretinal photocoagulation versus intravitreal anti-vascular endothelial growth factor. Ophthalmology 126:407–413
pubmed: 30077614 doi: 10.1016/j.ophtha.2018.07.027
Hirano T, Toriyama Y, Iesato Y, Imai A, Hirabayashi K, Nagaoka T, Takamura Y, Sugimoto M, Murata T (2017) Effect of leaking perifoveal microaneurysms on resolution of diabetic macular edema treated by combination therapy using anti-vascular endothelial growth factor and short pulse focal/grid laser photocoagulation. Jpn J Ophthalmol 61:51–60
pubmed: 27730425 doi: 10.1007/s10384-016-0483-8
Mansouri A, Sampat KM, Malik KJ, Steiner JN, Glaser BM, Medscape (2014) Efficacy of subthreshold micropulse laser in the treatment of diabetic macular edema is influenced by pre-treatment central foveal thickness. Eye (Lond) 28:1418–1424
doi: 10.1038/eye.2014.264
Jonas JB, Söfker A (2001) Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol 132:425–427
pubmed: 11530068 doi: 10.1016/S0002-9394(01)01010-8
Tao Y, Jonas JB (2011) Intravitreal triamcinolone. Ophthalmologica 225:1–20
pubmed: 20693817 doi: 10.1159/000317909
Mehta H, Hennings C, Gillies MC, Nguyen V, Campain A, Fraser-Bell S (2018) Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema. Cochrane Database Syst Rev 4:CD011599
pubmed: 29669176
Bakri SJ, Kaiser PK (2005) Posterior subtenon triamcinolone acetonide for refractory diabetic macular edema. Am J Ophthalmol 139:290–294
pubmed: 15733990 doi: 10.1016/j.ajo.2004.09.038
Shimura M, Nakazawa T, Yasuda K, Shiono T, Nishida K (2007) Pretreatment of posterior subtenon injection of triamcinolone acetonide has beneficial effects for grid pattern photocoagulation against diffuse diabetic macular oedema. Br J Ophthalmol 91:449–454
pubmed: 17077114 doi: 10.1136/bjo.2006.106336
Shimura M, Yasuda K, Nakazawa T, Shiono T, Sakamoto T, Nishida K (2009) Drug reflux during posterior subtenon infusion of triamcinolone acetonide in diffuse diabetic macular edema not only brings insufficient reduction but also causes elevation of intraocular pressure. Graefes Arch Clin Exp Ophthalmol 247:907–912
pubmed: 19343359 doi: 10.1007/s00417-009-1074-x
Shimura M, Yasuda K, Minezaki T, Noma H (2016) Reduction in the frequency of intravitreal bevacizumab administrations achieved by posterior subtenon injection of triamcinolone acetonide in patients with diffuse diabetic macular edema. Jpn J Ophthalmol 60:401–407
pubmed: 27306783 doi: 10.1007/s10384-016-0458-9
Shimura M, Yasuda K, Shiono T (2006) Posterior sub-Tenon’s capsule injection of triamcinolone acetonide prevents panretinal photocoagulation-induced visual dysfunction in patients with severe diabetic retinopathy and good vision. Ophthalmology 113:381–387
pubmed: 16458970 doi: 10.1016/j.ophtha.2005.10.035
Maturi RK, Glassman AR, Liu D, Beck RW, Bhavsar AR, Bressler NM, Jampol LM, Melia M, Punjabi OS, Salehi-Had H, Sun JK, Diabetic Retinopathy Clinical Research Network (2018) Effect of adding dexamethasone to continued ranibizumab treatment in patients with persistent diabetic macular edema: a DRCR Network phase 2 randomized clinical trial. JAMA Ophthalmol 136:29–38
pubmed: 29127949 doi: 10.1001/jamaophthalmol.2017.4914
Sun JK, Jampol LM (2019) The diabetic retinopathy clinical research network (DRCR.net) and its contributions to the treatment of diabetic retinopathy. Ophthalmic Res 62:225–230
pubmed: 31554001 doi: 10.1159/000502779
Lewis H, Abrams GW, Blumenkranz MS, Campo RV (1992) Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction. Ophthalmology 99:753–759
pubmed: 1594222 doi: 10.1016/S0161-6420(92)31901-3
Tachi N, Ogino N (1996) Vitrectomy for diffuse macular edema in cases of diabetic retinopathy. Am J Ophthalmol 122:258–260
pubmed: 8694095 doi: 10.1016/S0002-9394(14)72018-5
Terasaki H, Kojima T, Niwa H, Piao CH, Ueno S, Kondo M, Ito Y, Miyake Y (2003) Changes in focal macular electroretinograms and foveal thickness after vitrectomy for diabetic macular edema. Invest Ophthalmol Vis Sci 44:4465–4472
pubmed: 14507894 doi: 10.1167/iovs.02-1313
Kojima T, Terasaki H, Nomura H, Suzuki T, Mori M, Ito Y, Miyake Y (2003) Vitrectomy for diabetic macular edema: effect of glycemic control (HbA(1c)), renal function (creatinine) and other local factors. Ophthalmic Res 35:192–198
pubmed: 12815194 doi: 10.1159/000071170
Yamamoto T, Hitani K, Sato Y, Yamashita H, Takeuchi S (2005) Vitrectomy for diabetic macular edema with and without internal limiting membrane removal. Ophthalmologica 219:206–213
pubmed: 16088239 doi: 10.1159/000085729
Patel JI, Hykin PG, Schadt M, Luong V, Fitzke F, Gregor ZJ (2006) Pars plana vitrectomy with and without peeling of the inner limiting membrane for diabetic macular edema. Retina 26:5–13
pubmed: 16395132 doi: 10.1097/00006982-200601000-00002
Yanyali A, Horozoglu F, Celik E, Nohutcu AF (2007) Long-term outcomes of pars plana vitrectomy with internal limiting membrane removal in diabetic macular edema. Retina 27:557–566
pubmed: 17558316 doi: 10.1097/01.iae.0000249390.61854.d5
Hatano N, Mizota A, Tanaka M (2007) Vitreous surgery for diabetic macular edema--its prognosis and correlation between preoperative systemic and ocular conditions and visual outcome. Ann Ophthalmol (Skokie) 39:222–227
doi: 10.1007/s12009-007-0027-4
Hartley KL, Smiddy WE, Flynn HW Jr, Murray TG (2008) Pars plana vitrectomy with internal limiting membrane peeling for diabetic macular edema. Retina 28:410–419
pubmed: 18327132 doi: 10.1097/IAE.0b013e31816102f2
Kumagai K, Furukawa M, Ogino N, Larson E, Iwaki M, Tachi N (2009) Long-term follow-up of vitrectomy for diffuse nontractional diabetic macular edema. Retina 29:464–472
pubmed: 19289987 doi: 10.1097/IAE.0b013e31819c632f
Diabetic Retinopathy Clinical Research Network Writing Committee1, Haller JA, Qin H, Apte RS, Beck RR, Bressler NM, Browning DJ, Danis RP, Glassman AR, Googe JM, Kollman C, Lauer AK, Peters MA, Stockman ME (2010) Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction. Ophthalmology 117:1087–1093
doi: 10.1016/j.ophtha.2009.10.040
Simunovic MP, Hunyor AP, Ho IV (2014) Vitrectomy for diabetic macular edema: a systematic review and meta-analysis. Can J Ophthalmol 49:188–195
pubmed: 24767227 doi: 10.1016/j.jcjo.2013.11.012
Adelman R, Parnes A, Michalewska Z, Parolini B, Boscher C, Ducournau D (2015) Strategy for the management of diabetic macular edema: the European vitreo-retinal society macular edema study. Biomed Res Int 2015:352487
pubmed: 25695062 pmcid: 4324105
Terasaki H, Ogura Y, Kitano S, Sakamoto T, Murata T, Hirakata A, Ishibashi T (2018) Management of diabetic macular edema in Japan: a review and expert opinion. Jpn J Ophthalmol 62:1–23
pubmed: 29210010 doi: 10.1007/s10384-017-0537-6
Chhablani JK, Kim JS, Cheng L, Kozak I, Freeman W (2012) External limiting membrane as a predictor of visual improvement in diabetic macular edema after pars plana vitrectomy. Graefes Arch Clin Exp Ophthalmol 250:1415–1420
pubmed: 22354371 doi: 10.1007/s00417-012-1968-x
Yamada Y, Suzuma K, Ryu M, Tsuiki E, Fujikawa A, Kitaoka T (2013) Systemic factors influence the prognosis of diabetic macular edema after pars plana vitrectomy with internal limiting membrane peeling. Curr Eye Res 38:1261–1265
pubmed: 23972000 doi: 10.3109/02713683.2013.820327
Koyanagi Y, Yoshida S, Kobayashi Y, Kubo Y, Yamaguchi M, Nakama T, Nakao S, Ikeda Y, Ohshima Y, Ishibashi T, Sonoda KH (2016) Comparison of the effectiveness of intravitreal ranibizumab for diabetic macular edema in vitrectomized and nonvitrectomized eyes. Ophthalmologica 236:67–73
pubmed: 27362944 doi: 10.1159/000446992
Bressler SB, Melia M, Glassman AR, Almukhtar T, Jampol LM, Shami M, Berger BB, Bressler NM, Diabetic Retinopathy Clinical Research Network (2015) Ranibizumab plus prompt or deferred laser for diabetic macular edema in eyes with vitrectomy prior to anti-vascular endothelial growth factor therapy. Retina 35:2516–2528
pubmed: 26035510 pmcid: 4658280 doi: 10.1097/IAE.0000000000000617
Yamakiri K, Sakamoto T, Noda Y, Nakahara M, Ogino N, Kubota T, Yokoyama M, Furukawa M, Sonoda Y, Yamada T, Doi N, Enaida H, Hata Y, Ishibashi T (2007) Reduced incidence of intraoperative complications in a multicenter controlled clinical trial of triamcinolone in vitrectomy. Ophthalmology 114:289–296
pubmed: 17270679 doi: 10.1016/j.ophtha.2006.07.044
Reeser F, Fleischman J, Williams GA, Goldman A (1981) Efficacy of argon laser photocoagulation in the treatment of circinate diabetic retinopathy. Am J Ophthalmol 92:762–767
pubmed: 7198388 doi: 10.1016/S0002-9394(14)75626-0

Auteurs

Shigeo Yoshida (S)

Department of Ophthalmology, Kurume University School of Medicine, 67 Asahi-machi, Kurume-shi, Fukuoka, 830-0011, Japan. yoshi@med.kurume-u.ac.jp.

Tomoaki Murakami (T)

Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, 54 Shogoin-Kawaharacho, Sakyo-ku, Kyoto, 606-8507, Japan.

Miho Nozaki (M)

Department of Ophthalmology and Visual Science, Nagoya City University Graduate School of Medical Sciences, 1-Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya-Shi, Aichi, 467-8601, Japan.

Kiyoshi Suzuma (K)

Department of Ophthalmology, Kagawa University Faculty of Medicine, 1750-1 Ikenobe, Miki-cho, Kagawa, Kita-gun, 761-0793, Japan.

Takayuki Baba (T)

Department of Ophthalmology and Visual Science, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba, 260-8677, Japan.

Takao Hirano (T)

Department of Ophthalmology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto-shi, Nagano, 390-8621, Japan.

Osamu Sawada (O)

Department of Ophthalmology, Shiga University of Medical Science, Seta Tsukinowa-cho, Otsu-shi, Shiga, 520-2192, Japan.

Masahiko Sugimoto (M)

Department of Ophthalmology, Mie University Graduate School of Medicine, 2-174, Edobashi, Tsu-shi, Mie, 514-8507, Japan.

Yoshihiro Takamura (Y)

Department of Ophthalmology, Faculty of Medical Sciences, University of Fukui, 23-3, Matsuokashimoaizuki, Eiheiji-cho, Yoshida-gun, Fukui, 910-1193, Japan.

Eiko Tsuiki (E)

Department of Ophthalmology and Visual Sciences, Graduate School of Biomedical Sciences, Nagasaki University, Sakamoto 1-7-1, Nagasaki-shi, Nagasaki, 852-8523, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Inhibiteurs de l'angiogenèse › Review of clinical studies and recommendation...
questionsmedicales.fr › Maladies endocriniennes › Diabète › Review of clinical studies and recommendation...
questionsmedicales.fr › Maladies endocriniennes › Diabète › Complications du diabète › Angiopathies diabétiques › Rétinopathie diabétique › Review of clinical studies and recommendation...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Review of clinical studies and recommendation...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Voies d'administration de substances chimiques et des médicaments › Injections › Injections oculaires › Injections intravitréennes › Review of clinical studies and recommendation...
questionsmedicales.fr › Procédures de chirurgie opératoire › Procédures de chirurgie ophtalmologique › Photocoagulation › Coagulation par laser › Review of clinical studies and recommendation...
questionsmedicales.fr › Maladies de l'oeil › Rétinopathies › Dégénérescence de la rétine › Dégénérescence maculaire › Oedème maculaire › Review of clinical studies and recommendation...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Protéines angiogéniques › Facteurs de croissance endothéliale vasculaire › Facteur de croissance endothéliale vasculaire de type A › Review of clinical studies and recommendation...